Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | CD38 | P28907 | 1/20 | 0.46 |
| ▸ | CCR2 | P41597 | 2/20 | 0.45 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13802473 | 0.83 | MRGPRX4 (0.57) | CISD1MRGPRX4CD38APEX1MEN1 | |
| SCHEMBL4211567 | 0.80 | MAPT (0.71) | CCR2TSHRMEN1KMT2AMITF | |
| SCHEMBL6475183 | 0.80 | TDP1 (0.72) | FFAR1CCR2MEN1KMT2ARECQL | |
| SCHEMBL6475344 | 0.77 | MEN1 (0.64) | FFAR1CCR2MEN1KMT2ARECQL | |
| SCHEMBL13802478 | 0.75 | KDM4E (0.50) | APEX1MEN1KMT2AMITFRECQL | |
| SCHEMBL15818199 | 0.75 | KDM4C (0.67) | — | |
| SCHEMBL30299256 | 0.75 | KDM4C (0.67) | — | |
| SCHEMBL6475081 | 0.74 | MEN1 (0.49) | FFAR1CISD1CD38TSHRAPEX1 | |
| SCHEMBL15419642 | 0.74 | HSD17B10 (0.55) | FFAR1CISD1MRGPRX4MEN1KMT2A | |
| SCHEMBL9223914 | 0.72 | KDM4C (0.53) | TSHRAPEX1MEN1KMT2ARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | FFAR1 3064/4885CISD1 4368/4885MRGPRX4 2781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.